# A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

> **NCT01281579** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 50 mg
- **DRUG:** Canagliflozin 300 mg

## Key facts

- **NCT ID:** NCT01281579
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281579, "A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01281579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*